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Purpose. Methylglyoxal, a by-product of glycolysis and a precursor in the formation of advanced 25 
glycation end-products, is significantly elevated in the diabetic myocardium. Therefore, we sought to 26 
investigate the mitochondria-targeted methylglyoxal scavenger, MitoGamide, in an experimental 27 
model of spontaneous diabetic cardiomyopathy. 28 
Methods. Male 6-week-old Akita or wild type mice received daily oral gavage of MitoGamide or 29 
vehicle for 10 weeks. Several morphological and systemic parameters were assessed, as well as 30 
cardiac function by echocardiography. 31 
Results. Akita mice were smaller in size than wild type counterparts in terms of body weight and 32 
tibial length. Akita mice exhibited elevated blood glucose and glycated haemoglobin. Total heart and 33 
individual ventricles were all smaller in Akita mice. None of the aforementioned parameters were 34 
impacted by MitoGamide treatment. Echocardiographic analysis confirmed that cardiac dimensions 35 
were smaller in Akita hearts. Diastolic dysfunction was evident in Akita mice, and notably, 36 
MitoGamide treatment preferentially improved several of these markers, including e’/a’ ratio and 37 
E/e’ ratio. 38 
Conclusions. Our findings suggest that MitoGamide, a novel mitochondria-targeted approach, offers 39 
cardioprotection in experimental diabetes and therefore may offer therapeutic potential for the 40 





































































1 Introduction 42 
Diabetes is a well-known risk factor for the development of cardiovascular diseases, pertinent since 43 
the global incidence of diabetes is set to exceed 642 million by 2040 [1]. Cardiovascular disease is 44 
arguably the most important complication of diabetes, increasing heart failure risk 2.4-fold in diabetic 45 
men and 5-fold in diabetic women [2,3], but also accounting for the majority of healthcare costs and 46 
significantly reducing life expectancy. In one study, the 1-year mortality of heart failure was 30% in 47 
people with diabetes, about 1.5-fold greater than in those without diabetes [4]. Diabetic heart disease 48 
exists across a range of aetiologies, including coronary heart disease, diabetic cardiomyopathy and 49 
heart failure. Diabetes can expedite or even initiate changes in each disease scenario. For example, 50 
diabetes accelerates the progression of atherosclerosis in coronary arteries, exacerbates small vessel 51 
disease leading to increased cardiac load, compromised cardiac performance and eventual heart 52 
failure, and promotes detrimental cardiac remodelling characteristic of diabetic cardiomyopathy, 53 
including cardiomyocyte hypertrophy, elevated interstitial fibrosis and cardiomyocyte apoptosis [5]. 54 
The heart is the most metabolically-active organ in the body and possesses the highest amount of 55 
mitochondria, the powerhouses of the cell [6]. The high myocardial mitochondria content is 56 
absolutely critical in order to provide the tremendous amount of energy needed to maintain cardiac 57 
contraction and relaxation. In fact, despite the heart accounting for only 0.5% of body weight, it is 58 
responsible for 8% of ATP consumption [6]. Given that tissues with a greater metabolic demand are 59 
more susceptible to chronic complications, mitochondrial impairment has been implicated in the 60 
pathophysiology of diabetic heart disease [7]. Methylglyoxal, a by-product of glycolysis and a 61 
reactive carbonyl species, is significantly elevated in diabetes, and reacts with arginine and lysine 62 
residues to form irreversible carbonyl adducts [8]. Importantly, mitochondrial proteins are major 63 
targets of dicarbonyl glycation and are associated with increased reactive oxidative species formation 64 
and subsequent cardiac damage [9]. We hypothesise that the metabolic derangements indicative of 65 
diabetes, and subsequent dicarbonyl glycation, play a role in the development of diabetic 66 
cardiomyopathy. MitoGamide is an amide analogue of MitoG [10], which has been used to assess the 67 
accumulation of glyoxal and methylglyoxal in the mitochondria of the Akita mouse model of 68 
diabetes in vivo [10].  The two molecules share the methylglyoxal-scavenging diaminoaryl group and 69 
the mitochondria-targeting triphenylphosphonium moiety, but MitoGamide incorporates an amide 70 
link to facilitate synthesis and limit autooxidation. Therefore, in the present study we sought to 71 
investigate the cardioprotective potential of the novel mitochondria-targeted methylglyoxal 72 





































































2 Methods 74 
Animals 75 
All activities involving the use of animals for research were approved by the Alfred Medical 76 
Research Education Precinct (AMREP) Animal Ethics Committee and were conducted according to 77 
guidelines of the National Health and Medical Research Council of Australia for animal 78 
experimentation. For all experiments, we have included flow charts for the reporting of animal use 79 
and analysis in preclinical studies (Supplementary Fig. 1). The main aim of this study was to 80 
investigate the impact of MitoGamide treatment on cardiac function in an experimental model of 81 
diabetic cardiomyopathy. Accordingly, our primary endpoint was impact of MitoGamide treatment 82 
on e’/a’ ratio and E/A ratio, markers of LV diastolic function. Diabetic Akita mice (C57BL/6J-83 
Ins2Akita; heterozygous for the mutation) and their wild type (WT) counterparts were purchased 84 
from the Jackson Laboratory, bred at the AMREP Animal Centre and maintained under a 12h 85 
light/dark cycle. At 6 weeks of age, male littermates of both genotypes were assigned to receive 86 
either vehicle (10% ethanol in water), or MitoGamide (10 mg/kg) by daily oral gavage. Saphenous 87 
vein nonfasted blood glucose measurements (“High” measurements recorded at 33.3 mmol/L; 88 
ACCU-CHEK glucometer, Roche) and body weights were recorded on a weekly basis as part of 89 
animal monitoring. Glycated haemoglobin (HbA1c) was measured one week prior to study end using 90 
the Cobas B 101 system (Roche). Plasma insulin levels were measured using Mouse Ultrasensitive 91 
Insulin ELISA kit, as per manufacturer’s instructions (80-INSMSU-E01, ALPCO). At study end, 92 
animals received an overdose of sodium pentobarbital (80 mg/kg i.p.) prior to rapid excision and 93 
collection of hearts. 94 
Echocardiography 95 
Echocardiography was performed in anaesthetised mice (ketamine/xylazine/atropine: 100/10/0.96 96 
mg/kg i.p. at study endpoint utilising a Philips iE33 ultrasound machine with 15 MHz linear (M-97 
mode) and 12 MHz sector (Doppler) transducer. LV posterior wall (PWd) thickness, LV chamber 98 
dimensions and fractional shortening were assessed from M-mode imaging. LV filling was assessed 99 
using transmitral Doppler flow; the ratio of early (E) and atrial (A) blood flow velocities (E/A ratio), 100 
E-wave deceleration time were measured. Tissue Doppler echocardiography was used to assess the 101 
ratio of e’ velocity and a’ velocity (e’/a’ ratio). 102 
Statistical analysis 103 
Data were analysed with GraphPad Prism 8.01 statistical software package. All data are presented as 104 
mean ± standard error of the mean (SEM). Two-way analysis of variance (ANOVA) was used to 105 
detect main effects for genotype (WT vs Akita) and treatment (Vehicle vs. MitoGamide), followed 106 
by Tukey’s post hoc test to analyse the differences between individual experimental groups. 107 





































































3 Results 109 
Characterisation of diabetes and cardiac dimensions 110 
Male Akita or wild type mice at 6 weeks of age received daily oral gavage of MitoGamide or vehicle 111 
for a duration of 10 weeks (Fig. 1b). At study end, body weight and tibial length were smaller in 112 
diabetic mice compared to wild type (Table 1), consistent with previous reports using this model 113 
[11]. Blood glucose and glycated haemoglobin levels were significantly elevated in Akita mice 114 
(Table 1). Plasma insulin levels were reduced in Akita mice compared to wild type mice (Table 1). 115 
MitoGamide treatment had no effect compared to vehicle treatment on the aforementioned measures. 116 
Heart weight normalised to tibial length was significantly reduced in the Akita vehicle-treated mice 117 
compared to wild type vehicle-treated mice (Table 1). When LV weight and RV weight were 118 
considered independently, they mirrored the results seen in total heart weight (Table 1).  119 
Cardiac function 120 
Tissue Doppler imaging showed a significant decrease in peak e’ wave velocity in Akita vehicle-121 
treated mice compared to wild-type vehicle-treated mice (Fig. 1c), an effect attenuated by 122 
MitoGamide treatment. There was no difference between groups in terms of peak a’ velocity (Fig. 123 
1c). This translated into a significant decrease in e’/a’ ratio in the Akita vehicle-treated mice that was 124 
attenuated following MitoGamide treatment (Fig. 1d). There was a clear trend evident that 125 
MitoGamide treatment impacted the prolongation of deceleration time observed in vehicle-treated 126 
Akita mice (P=0.07, Fig. 1e). E/e’ ratio was reduced in MitoGamide-treated Akita mice compared to 127 
Akita vehicle mice (Fig. 1f). Doppler echocardiographic assessment of LV diastolic function 128 
indicated a significant decrease in E-wave velocity in Akita mice (Fig. 1g). However, there was no 129 
difference between groups in terms of peak A wave velocity (Fig. 1g). This translated to a significant 130 
reduction in E/A ratio, indicative of LV diastolic dysfunction (Fig. 1h); this impairment was not 131 
evident in MitoGamide-treated Akita mice. Representative images of tissue Doppler imaging and 132 
Doppler imaging are provided in Fig. 1i. These findings reveal that MitoGamide treatment in diabetic 133 
mice protects against the development of impaired ventricular relaxation.  134 
LV M-mode echocardiographic structure and systolic function were significantly different between 135 
wild type and Akita mice, indicated by a reduction in LV end-systolic and end-diastolic dimensions, 136 
including Ex-LVEDD, AWd, PWd and LVESD (Table 1). Fractional shortening was significantly 137 
elevated in Akita mice compared to age-matched wild type mice. Importantly, MitoGamide treatment 138 
exerted no impact on echocardiographic parameters of LV structure and M-mode-derived systolic 139 
function, and heart rate remained unchanged, between all groups for echocardiographic 140 





































































4 Discussion 142 
The key finding of this study is that novel compound MitoGamide, an amide variant of MitoG [10] 143 
and mitochondria-targeted methylglyoxal scavenger, offers cardioprotection in the Akita mouse 144 
model of spontaneous experimental diabetes. MitoGamide treatment exhibited no impact on the 145 
underlying diabetes phenotype, however MitoGamide preferentially improved several markers of LV 146 
diastolic dysfunction in diabetic mice. Given the well-established link between the increased global 147 
burden of diabetes and an increased risk of clinical heart failure [2], identification of new 148 
pharmacological treatment strategies designed specifically to target the underlying metabolic 149 
perturbations in disease pathogenesis is particularly timely [3]. 150 
Diabetes is a complex metabolic disease characterised primarily by hyperglycaemia but with many 151 
other interacting factors that lead to a broad range of complications, including diabetic heart disease. 152 
The rationale for this study was based on reports that methylglyoxal levels are elevated in diabetes 153 
[8,12], as the enzyme responsible for the removal of methylglyoxal, glyoxalase 1, becomes saturated. 154 
Accumulating levels of methylglyoxal provide an important precursor for the nonenzymatic 155 
glycation of proteins, affecting the structure and function of proteins and ultimately affecting 156 
intracellular events [10]. Mitochondrial proteins are major targets of dicarbonyl glycation and are 157 
associated with increased reactive oxidation species formation and subsequent cardiac damage [9]. 158 
Methylglyoxal affects several cellular functions such as insulin signalling, mitochondrial respiration 159 
and glycolysis, whilst high dose methylglyoxal therapy has been highlighted as a potential 160 
therapeutic option in cancer settings due to its cytotoxic effects [13]. Importantly, several 161 
mitochondria-targeted antioxidants confer beneficial improvements on cardiac function, although, to 162 
our knowledge, this is the first study to investigate the effect of a mitochondrial-targeted approach to 163 
reduce methylglyoxal levels in the diabetic heart.  164 
To specifically address the potential for selectively targeting mitochondrial methylglyoxal in the 165 
diabetic heart, we chose to employ an established genetic model of maturity onset diabetes of the 166 
young (MODY)4 and insulin insufficiency using the Ins2WT/C96Y Akita mouse model. Although this 167 
model may not be as clinically-relevant as one that mimics the more prevalent type 2 diabetes, 168 
utilising the Akita mouse model avoids the additional confounding factors of obesity and impaired 169 
leptin signalling evident in the most widely-accepted mouse model of type 2 diabetes that manifests 170 
detectable cardiac dysfunction, the spontaneously diabetic db/db mouse. Importantly, the Akita 171 
mouse model shares common structural and functional features of clinical diabetic cardiomyopathy 172 
and was therefore an appropriate choice for this study. Although the pathogenesis of type 1 and type 173 
2 diabetes are distinct at the systemic level, the changes that occur in the myocardium, and in 174 
particular the cardiac mitochondria, in both forms of diabetes, share numerous similarities [7]. 175 
The early stages of diabetic cardiomyopathy are commonly characterised by LV diastolic dysfunction 176 
and ventricular hypertrophy, and in later stages by LV systolic dysfunction progressing to 177 
decompensated heart failure [3,5]. Consistent with previous studies [14], our data confirm the 178 
presence of LV diastolic dysfunction at 16 weeks of age in Akita mice. Evaluation of both Doppler 179 
flow and tissue Doppler echocardiography revealed that 16 weeks of hyperglycaemia conferred a 180 
reduction in e’/a’ ratio and E/A ratio, and a prolongation of deceleration time (Fig. 1). Importantly, 181 
myocardial function of diabetic mice treated with MitoGamide for the final 10 weeks of the study, 182 
exhibited significant improvements in e’/a’ ratio and E/e’ ratio and a non-significant improvement in 183 
E/A ratio (P=0.16, Fig. 1), indicating that MitoGamide offers cardioprotection in this experimental 184 
model of diabetic cardiomyopathy. These reports are consistent with previous reports that 185 





































































methylglyoxal, in a type 1 model of diabetic cardiomyopathy, delayed and limited impairment in 187 
cardiac function [14]. At the time point in which cardiac function was assessed in our study, it is 188 
important to note that LV end-systolic and end-diastolic dimensions were smaller in the Akita mice 189 
and there was a significantly higher fractional shortening (Table 1). These findings are consistent 190 
with other studies using this model [15] and likely explained by the genetic nature of the model, 191 
where Akita mice exhibit smaller body weight, tibial length, heart and LV size when normalised to 192 
tibial length (Table 1). The phenotype of the Akita mouse hence precludes any inference regarding 193 
the presence or absence of LV systolic dysfunction in this model, however MitoGamide treatment 194 
did not affect any of these parameters (Table 1). 195 
Future directions, based on the findings outlined in this short communication, will likely include 196 
substantiating the role of MitoGamide in the more clinically-relevant setting of type 2 diabetes. 197 
Emphasis can then be placed on understanding the role, if any, of MitoGamide on mitochondrial 198 
function and oxidative stress. Furthermore, the current studies only describe the ability of 199 
MitoGamide to prevent the development of cardiac dysfunction, whereas future studies will 200 
determine the ability of MitoGamide to protect against established cardiac dysfunction, the most 201 
likely clinical scenario. This will include the use of serial echocardiography. Indeed, it is likely any 202 
novel treatment option that has efficacy in terms of cardiac function, will supplement (not replace) 203 
current therapeutic options in the management of disease. Further, one limitation of the current study 204 
was that it only included male mice. Future studies will determine if therapeutic intervention is 205 
effective in both male and female mice. 206 
Taken together, our data indicate that MitoGamide treatment confers cardioprotection in an 207 
experimental model of diabetic cardiomyopathy, and although further work is clearly required to 208 
elucidate the underlying mechanisms, our findings highlight a novel mitochondria-targeted approach 209 
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6 Abbreviations 251 
AWd  anterior wall diastolic thickness 252 
AMREP Alfred Medical Research Education Precinct  253 
ANOVA two-way analysis of variance  254 
BW  body weight 255 
Ex-LVEDD external LV end diastolic dimension 256 
LVESD LV end systolic dimension 257 
HbA1c  Glycated haemoglobin  258 
LV  left ventricular  259 
LVEDD LV end diastolic dimension 260 
PWd  posterior wall diastolic thickness 261 
SEM  standard error of the mean  262 
TL  tibial length  263 
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10 Figure Legends 292 
Fig. 1. MitoGamide treatment attenuates LV diastolic dysfunction in Akita mice. (a) The 293 
structure of MitoGamide. (b) Overview of experimental protocol. Tissue Doppler echocardiography 294 
was used to derive (c) peak e’ and peak a’ velocity, and (d) e’/a’ ratio. Doppler echocardiography 295 
was used to derive (e) deceleration time. (f) E/e’ ratio (g) peak E and peak A wave velocity, and (h) 296 
E/A ratio. (i) Representative images of Doppler and tissue Doppler echocardiography. Data are 297 
presented as mean ± SEM. n=8-13 per group. *P<0.05, **P<0.01, ****P<0.0001. Two-way 298 





































































11 Tables 300 
Table 1. Systemic characteristics, organ morphology and echocardiographic analysis of systolic heart function in 
anaesthetised wild type and Akita mice treated with MitoGamide or vehicle 





  Vehicle MitoGamide   Vehicle MitoGamide 
Systemic characteristics/organ morphology 
n 14 15   14 12 
Body weight (g) 29.9 ± 1.2 28.5 ± 0.5 
 
22.8 ± 0.9**** 23.7 ± 0.7** 
Tibial length (mm) 17.3 ± 0.1 17.1 ± 0.2 
 
16.7 ± 0.1* 16.4 ± 0.1** 
Blood glucose (mmol/L) 10.8 ± 0.6 11.7 ± 0.7 
 
33.0 ± 0.0**** 32.6 ± 0.4**** 
HbA1c (%) 4.60 ± 0.17 4.83 ± 0.16 
 
13.1 ± 0.35**** 13.3 ± 0.26**** 
Plasma insulin (ng/mL) 0.89 ± 0.04 0.92 ± 0.07 
 
0.75 ± 0.01* 0.78 ± 0.02 
Heart weight/tibial length (mg/mm) 9.19 ± 0.42 8.26 ± 0.33 
 
7.02 ± 0.13**** 7.72 ± 0.33 
LV/tibial length (mg/mm) 6.18 ± 0.27 5.57 ± 0.19 
 
4.50 ± 0.10**** 5.05 ± 0.16 
RV/tibial length (mg/mm) 1.64 ± 0.09 1.54 ± 0.08 
 
1.25 ± 0.06** 1.30 ± 0.07 
LV function 
n 12 13   9 10 
Heart rate (bpm) 399 ± 17 418 ± 11 
 
381 ± 10 385 ± 15 
Ex-LVEDD (mm) 5.75 ± 0.11 5.51 ± 0.09 
 
5.19 ± 0.05** 5.31 ± 0.09 
AWd (mm) 0.67 ± 0.02 0.67 ± 0.01 
 
0.60 ± 0.02* 0.61 ± 0.01* 
LVEDD (mm) 4.40 ± 0.12 4.19 ± 0.10 
 
4.01 ± 0.08 4.09 ± 0.12 
PWd (mm) 0.68 ± 0.02 0.68 ± 0.02 
 
0.60 ± 0.01*** 0.63 ± 0.01 
LVESD (mm) 3.15 ± 0.08 2.96 ± 0.10 
 
2.55 ± 0.09*** 2.58 ± 0.09* 
Fractional shortening (%) 28.3 ± 0.5 29.5 ± 1.0 
 
36.5 ± 1.6**** 37.0 ± 0.8**** 
Estimated LV mass (mg) 112 ± 5 101 ± 4 
 
81 ± 2*** 87 ± 3 
Estimated LV mass/BW (mg/g) 3.76 ± 0.19 3.53 ± 0.10 
 
3.68 ± 0.14 3.74 ± 0.21 
Estimated LV mass/TL (mg/mm) 6.47 ± 0.29 5.90 ± 0.24 
 
4.84 ± 0.13*** 5.29 ± 0.19 
Data are presented as mean ± SEM and analysed by two-way ANOVA followed by Tukey’s post-hoc test. *P<0.05, 
**P<0.01, ***P<0.001, ****P<0.0001 vs corresponding wildtype. Ex-LVEDD, external LV end diastolic dimension; Awd, 
anterior wall diastolic thickness; LVEDD, LV end diastolic dimension; PWd, posterior wall diastolic thickness; LVESD, LV 
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Figure 1 Click here to access/download;Figure;Figures_v3.0_First
Revision.pptx
Animals issued and allocated 
to groups: (n=61) 
6 weeks old, male FVB/N mice
Excluded: (n=0) 
Allocated to WT Vehicle: (n=14)
Received allocated intervention: (n=14)
Did not receive allocated intervention: (n=0)
Allocated to Akita Vehicle: (n=18)
Received allocated intervention: (n=18)
Did not receive allocated intervention: (n=0)
Allocated to WT MitoGamide: (n=15)
Received allocated intervention: (n=15)
Did not receive allocated intervention: (n=0)
Allocated to Akita MitoGamide: (n=14)
Received allocated intervention: (n=14)
Did not receive allocated intervention: (n=0)
Discontinued intervention: (n=0) Discontinued intervention: (n=0) Discontinued intervention: n=2 euthanised
due to diabetic complications
Discontinued intervention: n=4 euthanised
due to diabetic complications
Animals at endpoint: (n=14) Animals at endpoint: (n=15) Animals at endpoint: (n=14) Animals at endpoint: (n=12)
Included in body, organ weight and blood 
glucose measurements: (n=14)
Data not reported (n=0)
Included in HbA1C measurements: (n=8)
Reason: Smaller number of samples 
measured for logistical reasons.
Data not reported (n=0)
Included in plasma insulin measurements: 
(n=9)
Reason: Smaller number of samples 
measured for logistical reasons.
Data not reported (n=0)
Included in echocardiography 
measurements: (n=12)
Reason: One batch of mice did not undergo 
echocardiography due to core facility 
scheduling issues (n=2)
Data reported for M-mode echocardiography 
(n=12)
Data not reported for M-mode 
echocardiography (n=0)
Data reported for Doppler echocardiography 
(n=10)
Data not reported for Doppler 
echocardiography (n=2)
Reason: Heart rate <300bpm (n=1) or 
>500bpm (n=1) - no E/A wave separation.
Data reported for tissue Doppler 
echocardiography (n=12)
Data not reported for tissue Doppler 
echocardiography (n=0)
Included in body, organ weight and blood 
glucose measurements: (n=15)
Data not reported (n=0)
Included in HbA1C measurements: (n=9)
Reason: Smaller number of samples 
measured for logistical reasons.
Data not reported (n=0)
Included in plasma insulin measurements: 
(n=10)
Reason: Smaller number of samples 
measured for logistical reasons.
Data not reported (n=0)
Included in echocardiography 
measurements: (n=13)
Reason: One batch of mice did not undergo 
echocardiography due to core facility 
scheduling issues (n=2)
Data reported for M-mode echocardiography 
(n=13)
Data not reported for M-mode 
echocardiography (n=0)
Data reported for Doppler echocardiography 
(n=13)
Data not reported for Doppler 
echocardiography (n=0)
Included in tissue Doppler echocardiography 
measurements: (n=13)
Data not reported for tissue Doppler 
echocardiography (n=0)
Included in body, organ weight and blood 
glucose measurements: (n=14)
Data not reported (n=0)
Included in HbA1C measurements: (n=14)
Data not reported (n=0)
Included in plasma insulin measurements: 
(n=10)
Reason: Smaller number of samples 
measured for logistical reasons.
Data not reported (n=0)
Included in echocardiography 
measurements: (n=9)
Reasons: One batch of mice did not undergo 
echocardiography due to core facility 
scheduling issues (n=2) Three mice in three 
separate experiments did not respond to 
anaesthetic and did not undergo 
echocardiography at operator’s discretion 
(n=3)
Data reported for M-mode echocardiography 
(n=9)
Data not reported for M-mode 
echocardiography (n=0)
Data reported for Doppler echocardiography 
(n=7)
Data not reported for Doppler 
echocardiography (n=2)
Reason: No E/A wave separation (n=1) and 
extreme outlier identified as Q3+3*IQR (n=1).
Data reported for tissue Doppler 
echocardiography (n=7)
Data not reported for tissue Doppler 
echocardiography (n=2)
Reason: Heart rate >450bpm – no e’/a’wave
separation (n=1). Variable 
image/measurements (n=1)
Included in body, organ weight and blood 
glucose measurements: (n=12)
Data not reported (n=0)
Included in HbA1C measurements: (n=12)
Data not reported (n=0)
Included in plasma insulin measurements: 
(n=10)
Reason: Smaller number of samples 
measured for logistical reasons.
Data not reported (n=0)
Included in echocardiography 
measurements: (n=10)
Reason: One batch of mice did not undergo 
echocardiography due to core facility 
scheduling issues (n=2)
Data reported for M-mode echocardiography 
(n=10)
Data not reported for M-mode 
echocardiography (n=0)
Data reported for Doppler echocardiography 
(n=9)
Data not reported for Doppler 
echocardiography (n=1)
Reason: Heart rate <300bpm (n=1)
Data reported for tissue Doppler 
echocardiography (n=8)
Data not reported for tissue Doppler 
echocardiography (n=2)
Reason: Heart rate <250bpm (n=1) or 
>450bpm – no e’/a’ wave separation (n=1)
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